NASDAQ: AGMBAgomab Therapeutics Nv Stock
$9.88-0.45 (-4.36%)
Updated Jun 11, 2026
AGMB Price
$9.88
Fair Value Price
N/A
Market Cap
$481.52M
52 Week Low
$8.75
52 Week High
$17.45
P/E
-0.06x
P/B
3.16x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$73.58M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.17
Operating Cash Flow
-$61M
Beta
1.67
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
AGMB Overview
AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel, disease-modifying therapies. Its primary focus lies in immunology and inflammatory ailments, particularly chronic fibrotic conditions where significant unmet medical needs persist. Its innovative pipeline features several promising candidates, including Ontunisertib (AGMB-129), an orally administered, gastrointestinal-restricted small molecule inhibitor targeting ALK5 or TGFßR1, designed to treat Fibrostenosing Crohn's disease and presently undergoing Phase 2a clinical trials. Also in development is AGMB-447, an inhaled small molecule that similarly inhibits ALK5 or TGFßR1, intended for idiopathic pulmonary fibrosis and currently in Phase 1 clinical studies. Furthermore, the company is advancing AGMB-101, a monoclonal antibody designed to mimic HGF. This agent exerts its effects through the agonism or stimulation of the MET receptor, having demonstrated both antifibrotic and regenerative capabilities in preclinical models. Established in 2017, AgomAb Therapeutics maintains its headquarters in Antwerp, Belgium.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AGMB's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
AGMB
Ranked#127 of 463
Ranked#127 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $236.17 | A | |
| $53.50 | A | |
| $15.85 | A |
Be the first to know about important AGMB news, forecast changes, insider trades & much more!
AGMB News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AGMB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AGMB is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AGMB is good value based on its book value relative to its share price (3.16x), compared to the US Biotechnology industry average (4.83x)
P/B vs Industry Valuation
AGMB is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more AGMB due diligence checks available for Premium users.
Valuation
AGMB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.06x
Industry
17.66x
Market
13.95x
AGMB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.16x
Industry
4.83x
AGMB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AGMB's financial health
Profit margin
Revenue
$0.0
Net Income
-$20.5M
Profit Margin
0%
AGMB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$180.8M
Liabilities
$26.8M
Debt to equity
0.17
AGMB's short-term assets ($140.97M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AGMB's short-term assets ($140.97M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AGMB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$15.5M
Investing
-$35.3M
Financing
-$40.0k
AGMB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AGMB vs Biotech Stocks
Agomab Therapeutics Nv Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.